National Blood Clot Alliance

National Survey About Blood Clots and Stroke Risk Among Atrial Fibrillation Patients

Awareness, Information, Prevention, Adherence

Key Survey Findings for Healthcare Professionals

in Cardiology

Made Possible by a Grant from Janssen Pharmaceuticals, Inc.

www.stoptheclot.org

National Blood Clot Alliance

Patient GoverningBoard

Volunteer based, patient led

Science driven

Medical & Scientific Advisory Board

Dedicated to the prevention & quality treatment of blood clots

that cause DVTs, PEs, stroke

Awareness

Advocacy

Stop the Clot®

National Blood Clot Alliance

www.stoptheclot.org

Perspectives in Atrial Fibrillation (AF)

AF affects 2.6 million in the U.S.

Five-fold increased

risk for ischemic

stroke

Mortality rates have increased

in past two

decades

12 million AF cases projected by 2050

Overview: The NBCA AF Blood Clot/Stoke Awareness Survey

Responds to growing recognition of AF public health burdens

Benchmarks awareness, prophylaxis experiences

Demonstrates gaps in information and evidence-based prophylaxis

Methodology

Development

Questions developed bySurvey Steering Committee

MASAB members

Implementation

National survey firmInternet panels

2010 extensive evaluations 2011 data unveiled

Methodology

• Mean patient age 57.93 -- 4% aged 20-39 -- 82% aged 40-69 -- 14% aged 70-85+

• 53% female

Information

Prophylaxis

Adherence

Awareness500 AF patients

screened from an online panel

Blood Clot Awareness

Aware of blood clots Recognize blood clots as life threatening

91%

n=500 AF patients n=495 AF patients

99%

Risk Awareness/Information Sharing

27% 27%

60%

n=500 AF patients

Patient-Reported Prophylaxis Experiences

Aspirin Warfarin Low molecular weight heparin

67%

52%

12%

n=500 AF patients

Tx Difficulty of Use: Warfarin

Warfarin moderately/very diff...

32%

n=259 AF patients prescribed warfarin

Patient-Reported Treatment Barriers: Warfarin

70%63%

57%50% 48%

76%

n=84 AF patients prescribed warfarin who report it is moderately/very difficult to use

Additional Findings: Warfarin Adherence Among AF Patients

74% of 259 warfarin users report adherence

83% given information or education about the therapy

26% stopped therapy MD advised

Additional Findings: AF Patient Preferences

Therapeutic Options Cited by Patients to Optimize Treatment55% minimal bleeding complications, 52% fewer drug interactions,

46% no monitoring required, 43% fewer dietary restrictions

60% of AF Patients Given or Referred to Education/Information85% brochure/pamphlet, 37% Websites, 30% articles

12% books, 8% CDs/DVDs

AF Patients Say They PreferCD/DVD 93%, Websites 78%, books 74%,articles 72%, brochures/pamphlets 52%

Conclusions and Future Directions

Fill gaps related to blood clot/stroke risk awareness

Optimize education programs/prophylaxis among patients

Research new therapies to address treatment barriers

Opportunities exist for improved patient education

• General awareness is high• Gaps do remain

• Additional information limited• Information referrals limited

• Warfarin Tx barriers identified• Patients report adherence

• Aspirin use is high• Prophylaxis varies

Awareness

Information

Prophylaxis

Adherence

www.stoptheclot.org

Reduced risksand reduced

complications

Improved blood clot/stroke

understanding and prophylaxis

Decreased morbidity,

mortality, costs

Imperatives Moving Forward

www.stoptheclot.org

www.stoptheclot.org

Thank You for Your Commitment

The National Blood Clot Alliance thanks you for your commitment toincrease awareness of blood clots

and to help prevent blood clot complications like stroke.

Jack E. Ansell, MD - Steering Committee ChairChairman, Department of Medicine, Lenox Hill Hospital, Professor of Medicine,

New York University School of Medicine, New York, NY

Alan P. Brownstein, MPHChief Executive Officer, National Blood Clot Alliance, Tarrytown, NY

Richard J. Friedman, MD, FRCSCChairman, Department of Orthopaedic Surgery, Roper Hospital,

Clinical Professor of Orthopaedic Surgery, Medical University of South Carolina, Charleston, SC

Greg A. Maynard, MD, MSc, SFHMChief, Division of Hospital Medicine, University of California, San Diego, CA

Elizabeth A. Varga, MS, CGCCertified Genetic Counselor, National Children’s Hospital, Clinical Assistant Professor of Pediatrics,

The Ohio State University, Columbus, OH

www.stoptheclot.org

The National Blood Clot Alliance extends its appreciation to members of the NBCA Awareness Survey Steering Committee

LF&A, Inc.Lisa Fullam, President, Scottsdale, AZ

Dry Heat Productions, Inc.Scottsdale, AZ

Communications and Production Services

www.stoptheclot.org

The NBCA Awareness SurveyWas Made Possible by a Grant From

For More Information, Contact the National Blood Clot Alliance

On the Web: www.stoptheclot.org

On Facebook: www.facebook.com/stoptheclot

By phone: 877.4NO.CLOT 877.466.2568

©NBCA 2011